Natera Executive and Leadership Team

Steven Chapman, the Chief Executive Officer at Natera, directs the company's overarching strategy and vision, guiding Natera's mission to make personalized genetic testing a standard of care. Chapman's leadership focuses on advancing oncology, women's health, and organ health diagnostics, ensuring the company's research and development efforts align with market needs and patient well-being. Overseeing global operations, Chapman drives Natera's expansion and market penetration, emphasizing earlier and more targeted interventions. This executive role involves fostering innovation and ensuring the company's scientific advancements translate into tangible health benefits, supporting longer and healthier lives for patients worldwide. By championing the integration of cell-free DNA testing into routine medical practice, Steven Chapman solidifies Natera's position as a leader in genetic diagnostics.

Michael Brophy, the Chief Financial Officer at Natera, manages the company's financial strategy and resources, ensuring fiscal health and supporting Natera's ambitious growth objectives. Brophy oversees all financial operations, including budgeting, forecasting, and capital allocation, critical for funding research and development in oncology, women's health, and organ health diagnostics. This executive function is vital for sustaining Natera's commitment to making personalized genetic testing a standard of care and enabling earlier, more targeted interventions. By guiding financial planning, Michael Brophy ensures the company can continue to invest in innovations that support longer, healthier lives for patients. The CFO's strategic financial management is instrumental in Natera's ability to expand its market reach and solidify its position as a leader in genetic diagnostics.

Constance O'Sagie, the Chief Operating Officer at Natera, executes the operational strategies that support the company's growth and service delivery. O'Sagie manages the day-to-day functions critical to Natera's global operations, ensuring efficient scaling of its cell-free DNA testing services across oncology, women's health, and organ health. This leadership position involves optimizing laboratory processes, supply chain management, and customer support to meet the increasing demand for personalized genetic diagnostics. By streamlining workflows, Constance O'Sagie enhances the accessibility and reliability of Natera's diagnostic solutions, directly contributing to the company's goal of making advanced genetic testing a standard of care. The operational oversight ensures that Natera can effectively deliver on its promise of enabling earlier, more targeted interventions for improved patient outcomes.

Rishi Kacker, the Chief Technology Officer at Natera, architects the technological infrastructure and innovation pipeline that underpins the company's advanced cell-free DNA testing. Kacker directs the development and implementation of cutting-edge technologies essential for Natera's leadership in oncology, women's health, and organ health diagnostics. This role involves overseeing data science, bioinformatics, and software engineering to enhance the precision and scope of genetic testing. By driving technological advancements, Rishi Kacker ensures Natera's platforms can support earlier, more targeted interventions, aligning with the company's mission to improve patient health outcomes. The CTO's focus on scalable and robust technological solutions is critical for integrating personalized genetic diagnostics into standard medical practice and enabling longer, healthier lives.